Denosumab
Denosumab is a pharmaceutical drug with 162 clinical trials. Currently 21 active trials ongoing. Historical success rate of 88.0%.
Success Metrics
Based on 103 completed trials
Phase Distribution
Phase Distribution
22
Early Stage
49
Mid Stage
73
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.1%
103 of 121 finished
14.9%
18 ended early
21
trials recruiting
162
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Denosumab for Type 1 Diabetes
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Sequential Therapies After Osteoanabolic Treatment
Denosumab for Smoldering Multiple Myeloma
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months
Clinical Trials (162)
Denosumab for Type 1 Diabetes
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Sequential Therapies After Osteoanabolic Treatment
Denosumab for Smoldering Multiple Myeloma
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months
Markers of Osteoporosis in Cystic Fibrosis
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Denosumab Strategy for Liver Cancer With Bone Metastases
Anabolic Therapy in Postmenopausal Osteoporosis
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
RANKL Inhibition and Mammographic Breast Density
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
Muscle Impact of Treating Osteoporosis
NAPO - Novel Approach for Oligospermia
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 162